Clinical Scorecard: Clinical Insights and Outcomes of Superficial Cervicovaginal Myofibroblastoma: A Report on Two Cases and Literature Review

At a Glance

Key Highlights

• SCVM is clinically rare, representing less than 0.1% of benign tumors.
• Common symptoms include irregular vaginal bleeding and incidental findings.
• Surgical excision is the primary treatment with a favorable prognosis and low recurrence rate.
• Accurate diagnosis requires histopathological and immunohistochemical evaluation.
• The tumor demonstrates hormone-related characteristics and slow growth.

Guideline-Based Recommendations

Diagnosis

• Utilize integrated evaluation of histopathological morphology and immunohistochemical profiles.

Management

• Surgical resection is recommended as the primary treatment approach.

Monitoring & Follow-up

• Follow-up periods should be conducted to monitor for recurrence, typically ranging from 6 months to 1 year.

Risks

• Misdiagnosis or overtreatment due to overlapping features with other soft tissue tumors.

Patient & Prescribing Data

Female patients aged 20–60 years with SCVM.

Surgical excision is effective with no reported recurrence in follow-up.

Clinical Best Practices

• Conduct thorough gynecological examinations to identify incidental findings.
• Employ imaging techniques like gynecological ultrasonography for initial assessment.
• Ensure comprehensive pathological analysis to differentiate SCVM from other tumors.

Related Resources & Content

• Clinical Insights and Outcomes of Superficial Cervicovaginal Myofibroblastoma